IDEXX Laboratories, Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Health Care Equipment and Supplies | Market Cap: ₹44.8K Cr
- Full-year 2026 revenue outlook increased to $4.675B-$4.76B, reflecting a $32M constant currency improvement on strong Q1 results. - Full year 2026 revenue guidance increased to $4.675 billion to $4.76 billion, up $42 million at midpoint.
From IDEXX Laboratories, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹568.03
Market Cap
₹44.8K Cr
P/E Ratio
41.0
Revenue Rank
Margin Rank
How does IDEXX Laboratories, Inc. rank in Health Care Equipment and Supplies?
Compare IDEXX Laboratories, Inc. against every Health Care Equipment and Supplies company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →Full-year 2026 revenue outlook increased to $4.675B-$4.76B, reflecting a $32M constant currency improvement on strong Q1 results.
- →Organic revenue growth projected at 7.7%-9.7%, with CAG Diagnostics recurring revenue growth at 8.7%-10.7%, driven by volume gains and ~4% net price realization.
- →Instrument placements for inVue Dx expected to reach 5,500 in 2026, with strong commercial execution and widening adoption of innovations (e.g., Cancer DX, F&A launch ramping in 2H).
- →Clinical visits expected to decline modestly (-1.5% in U.S.) but offset by expanding diagnostic frequency and utilization per visit.
- →International markets anticipated for continued double-digit growth due to long-term investments, innovation, and commercial expansion.
- →Positive momentum seen from aging pet population driving increased visits and diagnostic usage.
- →Supply chain disruptions mainly in Water business (Middle East) factored into outlook but being managed.
- →Continued investments in AI and software to accelerate future growth.
📈 Profitability & Margins
Rank 2- →Full year 2026 revenue guidance increased to $4.675 billion to $4.76 billion, up $42 million at midpoint.
- →Reported revenue growth outlook: 8.6% to 10.6% for 2026.
- →Organic revenue growth outlook: 7.7% to 9.7% overall; 8.7% to 10.7% for CAG Diagnostic recurring revenue.
- →Comparable operating margin improvement expected at 50 to 90 basis points for full year 2026.
- →Updated operating margin guidance: 32.1% to 32.5% for 2026.
- →EPS outlook raised to $14.45 to $14.90 per share, up $0.13 at midpoint.
- →EPS growth forecasted at 11% to 15% on a comparable basis.
- →Q2 2026 revenue growth guidance: 7.3% to 9.3%, with operating margin expansion of 10 to 50 basis points.
- →Operating expenses expected to rise modestly due to ongoing investments and timing of projects.
🏗️ Capital Expenditure Plans
Yes- →Full year capital spending forecasted at approximately $180 million for 2026.
- →Investments focused on advancing global commercial and innovation capabilities.
- →Continued expansion of field-based presence in key geographies to support commercial reach.
- →Investments in innovation-driven platform growth strategy, including diagnostics and software.
- →Development of AI capabilities embedded in platforms like inVue Dx and ezyVet, with more advancements planned.
- →Growing cloud-native software offerings and diagnostic platforms such as Cancer DX and inVue Dx.
- →Expansion of international markets through localized software solutions (e.g., VetConnect PLUS) and commercial expansion.
- →Commitment to sustaining innovation pipeline and supporting long-term growth through strategic investments.
💰 Fundraising & Capital Structure
No information- →The transcript does not mention any current or future fundraising plans through debt or equity.
- →The company reported strong financial performance with low leverage ratios (0.6x gross and 0.5x net of cash).
- →Capital deployment during Q1 focused on share repurchases totaling $361 million.
- →Free cash flow and profitability remain strong, with no indications of needing external fundraising.
- →There is no discussion or guidance about issuing new debt or equity in the provided pages.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Health Care Equipment and Supplies this season
- Insulet Corporation (Q2 FY26)
Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24
- Globus Medical, Inc. (Q2 FY26)
Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.
- Align Technology, Inc. (Q2 FY26)
Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap
- Solventum Corporation (Q2 FY26)
Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag
Frequently Asked Questions
What were IDEXX Laboratories, Inc. Q2 FY26 results?
- Full-year 2026 revenue outlook increased to $4.675B-$4.76B, reflecting a $32M constant currency improvement on strong Q1 results. - Full year 2026 revenue guidance increased to $4.675 billion to $4.76 billion, up $42 million at midpoint.
What is IDEXX Laboratories, Inc. share price analysis?
IDEXX Laboratories, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 41.0 with a market cap of $44,808. Investors should review the full earnings analysis for detailed insights.
Is IDEXX Laboratories, Inc. planning capital expenditure?
- Full year capital spending forecasted at approximately $180 million for 2026.
Keep IDEXX Laboratories, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.